Press release
Infantile Spasm Market is expected to reach USD 590 million by 2034
Infantile Spasm
Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/71941
The global market is expanding due to growing awareness, improved access to diagnostics, and therapeutic innovation, including hormonal therapies, anti-seizure medications, and genetic research into underlying causes.
Market Overview
• Market Size (2024): USD 310 million
• Forecast (2034): USD 590 million
• CAGR (2025-2034): 6.6%
Growth is supported by expanded newborn epilepsy screening, pipeline therapies, and global rare disease funding.
Key Highlights:
• IS incidence estimated at 2-5 per 10,000 live births.
• Standard therapies include adrenocorticotropic hormone (ACTH), vigabatrin, corticosteroids.
• Genetic testing increasingly identifies causes such as TSC, CDKL5 deficiency, and metabolic disorders.
• Orphan drug incentives driving R&D in rare epilepsies.
Segmentation Analysis
By Product Type:
• Pharmacological Therapies
o ACTH (gold standard)
o Vigabatrin (especially in Tuberous Sclerosis Complex-related IS)
o Corticosteroids (prednisolone, dexamethasone)
o Anti-Seizure Medications (valproate, topiramate, clobazam - adjunctive)
o Pipeline Agents (gene-targeted therapies, novel ASMs)
• Non-Pharmacological Therapies
o Diet
o Vagus Nerve Stimulation (VNS - rare, refractory cases)
o Behavioral & Developmental Therapy
• Diagnostics
o EEG (Hypsarrhythmia detection)
o MRI & CT Imaging (structural abnormalities)
o Genetic & Metabolic Testing
By Platform:
• Small Molecules (vigabatrin, corticosteroids, ASMs)
• Biologics (ACTH, monoclonals in pipeline)
• Genetic Diagnostics
• Dietary & Device-Based Interventions
By Technology:
• Next-Generation Sequencing (NGS) for epilepsy gene panels
• Digital EEG Monitoring & AI Interpretation
• Gene Therapy & ASO Platforms (pipeline)
By End Use:
• Hospitals & Pediatric Neurology Clinics
• Epilepsy Specialty Centers
• Diagnostic Laboratories
• Research Institutes
By Application:
• TSC-Associated IS
• Structural Brain Malformation-Associated IS
• Genetic & Metabolic IS
• Idiopathic IS
• Clinical Research
Segmentation Summary:
ACTH and vigabatrin remain standards of care, but genetic testing and precision therapies are driving the fastest growth. The genic diet continues as an effective adjunct.
Explore Full Report here: https://exactitudeconsultancy.com/reports/71941/infantile-spasm-market
Regional Analysis
North America
• ~44% share in 2024.
• Strong orphan drug incentives and advanced pediatric neurology infrastructure.
• FDA approvals of vigabatrin and ACTH driving adoption.
Europe
• ~28% share.
• EMA approvals of vigabatrin and access to genetic epilepsy testing.
• Germany, UK, and France leading rare epilepsy research.
Asia-Pacific
• Fastest-growing region with CAGR of ~7.5%.
• Rising incidence recognition in Japan, China, and India.
• Expanding neonatal neurology and genetic testing programs.
Middle East & Africa
• Smaller share but significant unmet need.
• Limited access to ACTH and vigabatrin outside urban centers.
Latin America
• Brazil and Mexico driving regional adoption.
• Gradual improvement in pediatric epilepsy infrastructure.
Regional Summary:
North America and Europe dominate due to orphan drug policies and access to therapies, while Asia-Pacific grows fastest due to expanding diagnosis and rare disease infrastructure.
Market Dynamics
Key Growth Drivers:
• Rising awareness of infantile spasms and early diagnosis.
• Expanding access to ACTH, vigabatrin, and genic therapy.
• Growing role of genetic testing and precision medicine.
• Orphan drug incentives supporting R&D.
Key Challenges:
• Lack of curative therapies; high relapse and long-term disability risk.
• Limited access to ACTH in low-income countries.
• High costs of genetic testing and orphan drugs.
• Small patient pool complicating large clinical trials.
Latest Trends:
• Expansion of gene-targeted therapies and ASOs for epilepsy syndromes.
• AI-driven EEG interpretation for early detection.
• Clinical trials in novel GABA modulators and neurosteroids.
• Digital health platforms supporting rare epilepsy families.
Get Your Exclusive Offer with up to 10% Discount : https://exactitudeconsultancy.com/checkout/?currency=USD&type=single_user_license&report_id=71941
Competitor Analysis
Major Players in the Market:
• Mallinckrodt Pharmaceuticals (ACTH - H.P. Acthar Gel)
• Lundbeck A/S (Vigabatrin - Sabril)
• Eisai Co., Ltd.
• UCB Pharma (anti-seizure medications)
• Novartis AG
• Biogen Inc. (rare epilepsy research)
• Roche Holding AG (genetic epilepsy pipeline)
• GW Pharmaceuticals
• Ionis Pharmaceuticals, Inc. (ASO pipeline)
• Sarepta Therapeutics (gene therapy research)
Competitive Summary:
Mallinckrodt and Lundbeck dominate current standards (ACTH and vigabatrin). Eisai, UCB, and GW Pharmaceuticals contribute with anti-seizure therapies. Biogen, Roche, Ionis, and Sarepta lead the genetic and ASO pipeline. Competition focuses on gene-targeted approaches, orphan drug approvals, and digital neurology tools.
Conclusion
The Infantile Spasm Market, valued at USD 310 million in 2024, is projected to reach USD 590 million by 2034, growing at a CAGR of 6.6%. Advances in hormonal therapy access, genetic testing, and pipeline precision therapies will continue to shape this market.
Key Takeaways:
• ACTH and vigabatrin remain first-line therapies.
• North America and Europe dominate, while Asia-Pacific grows fastest.
• Genetic testing and AI-driven EEG diagnostics are expanding adoption.
• Future care will shift toward gene-targeted and precision pediatric approaches.
The next decade will transform IS care from limited pharmacological management to integrated multimodal care, creating opportunities for pharma, biotech, and digital innovators in rare pediatric neurology.
This report is also available in the following languages : Japanese (乳児けいれん市場), Korean (유아 경련 시장), Chinese (婴儿痉挛市场), French (Marché des spasmes infantiles), German (Markt für infantile Spasmen), and Italian (Mercato degli spasmi infantili), etc.
Request for a sample of this research report at (Use Corporate Mail ID for Quick Response) @ https://exactitudeconsultancy.com/reports/71941/infantile-spasm-market#request-a-sample
Our More Reports:
Glaucoma Patient Pool Analysis, Market
https://exactitudeconsultancy.com/reports/72297/glaucoma-patient-pool-analysis-market
Dry AMD Patient Pool Analysis, Market
https://exactitudeconsultancy.com/reports/72296/dry-amd-patient-pool-analysis-market
Uveitis Market
https://exactitudeconsultancy.com/reports/72295/uveitis-market
About Us
Exactitude Consultancy is a market research & consulting services firm which helps its client to address their most pressing strategic and business challenges. Our market research helps clients to address critical business challenges and also helps make optimized business decisions with our fact-based research insights, market intelligence, and accurate data.
https://bulletin.exactitudeconsultancy.com/
https://www.thehealthanalytics.com/
https://www.analytica.global/
https://www.marketintelligencedata.com/
https://www.marketinsightsreports.com/
https://exactitudeconsultancy.com/
Connect Us:
Irfan Tamboli
PHONE NUMBER +1 (704) 266-3234
EMAIL ADDRESS: sales@exactitudeconsultancy.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Infantile Spasm Market is expected to reach USD 590 million by 2034 here
News-ID: 4180863 • Views: …
More Releases from Exactitude Consultancy
Intracerebral Hemorrhage (ICH) Market is expected to reach USD 5.1 billion by 20 …
Intracerebral hemorrhage (ICH) is a severe subtype of stroke characterized by bleeding directly into the brain tissue, often caused by hypertension, cerebral amyloid angiopathy, trauma, or anticoagulant therapy. ICH accounts for 10-15% of all strokes but is associated with disproportionately high rates of mortality and disability.
Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/71943
Currently, management focuses on emergency stabilization, blood pressure control, surgical evacuation in selected cases, and reversal…
Levodopa-Induced Dyskinesia (LID) Market is expected to reach USD 3.0 billion by …
Levodopa remains the gold standard therapy for Parkinson's disease (PD), effectively managing motor symptoms. However, long-term use often leads to levodopa-induced dyskinesia (LID), characterized by involuntary, erratic, and often debilitating movements. LID significantly affects quality of life, complicating treatment strategies for PD patients.
Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/71945
The condition has driven intense clinical research into adjunctive therapies, novel formulations, neuromodulation devices, and digital monitoring tools.…
Lumbosacral Radicular Pain Market is expected to reach $11.7 billion by 2034
Lumbosacral radicular pain, commonly referred to as sciatica, is a neuropathic pain condition caused by compression or irritation of the lumbosacral nerve roots. It typically results from herniated discs, lumbar spinal stenosis, degenerative disc disease, or trauma, and is characterized by sharp radiating pain, numbness, tingling, or weakness in the lower back and legs.
Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/71947
The condition significantly impacts quality of life and…
Multiple Organ Dysfunction Syndrome (MODS) Market to Reach USD 9.7 Billion by 20 …
Multiple Organ Dysfunction Syndrome (MODS) is a life-threatening condition characterized by progressive failure of two or more organ systems, often resulting from sepsis, severe trauma, burns, or systemic inflammatory response syndrome (SIRS). It is the leading cause of death in intensive care units (ICUs) worldwide, with mortality rates ranging between 30-80% depending on severity.
Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/71949
As global populations age and chronic conditions increase,…
More Releases for ACTH
ACTH ELISA Test Kit Market Key Players, Share and Forecast Outlook
"The global market for ACTH ELISA test kits is valued at approximately $150 million in 2024, with a projected value of around $280 million by 2034. This represents a Compound Annual Growth Rate (CAGR) of approximately 6.5% during the forecast period from 2025 to 2034. "
Exactitude Consultancy., Ltd. released a research report titled "ACTH ELISA Test Kit Market". This report covers the global ACTH ELISA Test Kit market sales, sales…
Innovative Horizons in the ACTH (1-39) Market: Trends and Leading Players
In today's dynamic global economy, the ACTH (1-39) market is emerging as a beacon of opportunity and innovation. With rapid technological advancements, evolving consumer demands, and proactive government policies shaping the landscape, this sector is setting the stage for transformative change. Our in-depth analysis delves into historical market trends, current dynamics, and future projections, providing industry leaders, investors, and decision-makers with the strategic insights needed to navigate this competitive terrain.
𝐆𝐞𝐭…
ACTH Deficiency Market is growing at a healthy CAGR 7.00% by 2028
Global ACTH Deficiency market is expected to gain market growth in the forecast period of 2021 to 2028. Data Bridge Market Research analyses the market is growing at a healthy CAGR 7.00% in the above-mentioned research forecast period. Rising prevalence of rare disorders such as Addison Disease, Gigantism, Cushing Syndrome, Childhood Obesity and others are the factors responsible for the growth of this market.
However, a rising population with unhealthy lifestyles…
Adrenocorticotropic Hormone [ACTH] Market to Record an Exponential CAGR by 2031
Adrenocorticotropic Hormone (ACTH) Market: Introduction
According to the report, the global adrenocorticotropic hormone (ACTH) market was valued at US$ 1.3 Bn in 2020 and is projected to expand at a CAGR of 3.9% from 2021 to 2031. Need for the development of newer and technologically enhanced products is rising globally, owing to treatment efficiency of drugs. Hence, major players operating in the market invest in research & development in order to develop new drugs. The rise in…
Adrenocorticotropic Hormone (ACTH) Market 2022: Mallinckrodt, Pfizer, Novartis A …
Adrenocorticotropic Hormone (ACTH) Market research report studies the competitive development of the market, such as agreements, new product launches, expansions, and acquisitions in the market. In addition, it provides a region-wise study of the market, including North America, Asia Pacific, Latin America, the Middle East, Africa, and Europe. As a result, it helps stakeholders understand market players and analyze the top 25 organizations based on their product footprint, market strength,…
ACTH Deficiency Treatment Market Analysis & Key Business Strategies by Leading I …
Adenocorticotropic hormone (ACTH) is produced and secreted by anterior pituitary gland. It is also called corticotropin, serum ACTH, etc. The hormone’s function is to regulate the levels of steroid hormone cortisol which is regulated by adrenal gland. ACTH is associated with diseases such as pituitary tumors and adrenal malfunctions. Deficiency of ACTH arises due to the absence or decreased production of adrenocorticotropic hormone, which leads to adrenal insufficiency. This results…
